Novartis AG is temporarily pausing screening, randomization and treatment across rapcabtagene autoleucel trials in autoimmune diseases.
The RAP-CEL program in oncology is not affected by this halt.
The pause follows notification of 3 serious immune effector cell associated hemophagocytic syndrome events, resulting complications led to fatal outcomes.
NVS•
